Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...
Faking it on the phone: How to tell if a voice call is AI or not Can you believe your ears? Increasingly, the answer is no. Here’s what’s at stake for your business, and how to beat the deepfakers. Is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results